CLINICAL TRIALS PROFILE FOR AURYXIA
✉ Email this page to a colleague
All Clinical Trials for AURYXIA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01554982 ↗ | A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on Dialysis | Completed | Keryx Biopharmaceuticals | Phase 3 | 2012-08-01 | A long-term safety study of ferric citrate (KRX-0502) in renal failure patients who have completed study KRX-0502-304. Only patients who participated in the KRX-0502-304 trial may participate in this trial. |
| NCT02492620 ↗ | Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D | Completed | Keryx Biopharmaceuticals | Phase 3 | 2015-03-01 | It is the investigators hypothesis that participants treated with Ferric Citrate (FC) during the non-dialysis CKD stage (4/5) with sufficient duration prior to initiating RRT, will result in improved biochemical control of anemia (Hb, TSAT) and mineral metabolism (P, FGF23) and furthermore, will result in a reduced need for ESA and intravenous iron. The investigators further hypothesize that effective treatment of anemia and mineral metabolism with FC in the pre-dialysis and transition period will result in improved physical functioning, reduced hospitalization and reduced total cost of care when compared to participants receiving contemporaneously provided standard of care therapy. |
| NCT02492620 ↗ | Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D | Completed | Denver Nephrologists, P.C. | Phase 3 | 2015-03-01 | It is the investigators hypothesis that participants treated with Ferric Citrate (FC) during the non-dialysis CKD stage (4/5) with sufficient duration prior to initiating RRT, will result in improved biochemical control of anemia (Hb, TSAT) and mineral metabolism (P, FGF23) and furthermore, will result in a reduced need for ESA and intravenous iron. The investigators further hypothesize that effective treatment of anemia and mineral metabolism with FC in the pre-dialysis and transition period will result in improved physical functioning, reduced hospitalization and reduced total cost of care when compared to participants receiving contemporaneously provided standard of care therapy. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for AURYXIA
Condition Name
Clinical Trial Locations for AURYXIA
Trials by Country
Clinical Trial Progress for AURYXIA
Clinical Trial Phase
Clinical Trial Sponsors for AURYXIA
Sponsor Name
